drug_type
RELEVANT_DRUG
intervention_type
Cell therapy (allogeneic CAR T cells)
drug_description
Allogeneic (off-the-shelf) UCAR-T cell therapy engineered with a mesothelin (MSLN)-specific chimeric antigen receptor; upon antigen engagement, CAR T cells activate cytotoxic programs (immune synapse formation, perforin/granzyme release, cytokine secretion) to lyse MSLN-expressing tumor cells. Administered by arterial infusion for MSLN-positive advanced pancreatic cancer.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Arterial infusion
drug_mechanism_of_action
Allogeneic (off‑the‑shelf) T lymphocytes engineered to express a mesothelin (MSLN)-specific chimeric antigen receptor. CAR engagement of MSLN on tumor cells triggers T‑cell activation and cytotoxic effector functions (immune synapse formation, perforin/granzyme release, cytokine secretion), leading to targeted lysis of MSLN‑expressing cancer cells.
drug_name
CHT102
nct_id_drug_ref
NCT06760364